

JUL 10, 2023

Fura-2 imaging of ionomycin response, with and without R568; a CaSR positive modulator

In 1 collection

Peter Kilfeather¹

¹University of Oxford



Peter Kilfeather

ABSTRACT

Fura-2 imaging protocol to accompany Kilfeather, Khoo et al., 2023: **Single cell** spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease

OPEN ACCESS

DOI:

dx.doi.org/10.17504/protocol s.io.kqdg39p4zg25/v1

Protocol Citation: Peter Kilfeather 2023. Fura-2 imaging of ionomycin response, with and without R568; a CaSR positive modulator. **protocols.io** https://dx.doi.org/10.17504/protocols.io.kqdg39p4zg25/v1

License: This is an open access protocol distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working We use this protocol and it's working

Created: Oct 18, 2022

Last Modified: Jul 10, 2023

PROTOCOL integer ID:

71468

Data Capture

- 1 Prepare Fura-2 AM to 5 mM concentration in calcium-free HBSS supplemented with 20 mM HEPES.
- Dilute Fura-2 AM to the final concentration of 2.5 mM in Neurobasal medium supplemented with B27 and L-glutamine, with DMSO (0.1%) or the CaSR positive modulator R568 (10 mM).
- Incubate iPSC-derived dopaminergic neurons (DAns) in the solution of Fura-2 AM and drug for 1 h at 37°C, 5% CO₂ and then image on a FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices) at 37°C.
- 4 Excite the dye at 340 nm and 380 nm and detect at 510 nm. Image each well every 4 s for 100 s and inject with ionomycin (final concentration 5 mM) after a baseline of 28 s.

Analysis

For the analysis, compute the 340/380 ratio, and then subtract the baseline from all the timepoints, to obtain a normalised trace for each well. Find the maximum intensity (peak amplitude) of the normalised trace and calculate the area under the curve (AUC) using the left rectangular approximation method.